Company News

Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in…

Orthocell has announced that results from the Remplir™ nerve regeneration clinical trial have been published in a high profile clinical…

Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial…

Orthocell has today published its Quarterly Report for the period ended 31 March 2024.

Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair…

Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.

Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for…

Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent…

Orthocell has today released positive results from our clinical study comparing OrthoATI™ to surgery for the treatment of severe chronic…

Orthocell has today announced the appointment of one of Australia’s most innovative and respected plastic and reconstructive surgeons and researchers,…